{
    "info": {
        "nct_id": "NCT03833661",
        "official_title": "A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy",
        "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Ampullary cancer was excluded\n* Significant acute or chronic infections\n* Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent\n* Interstitial lung disease or its history\n* Participants who were not eligible for or have not been treated with 1L systemic chemotherapy\n* Anticancer treatment within 21 days before the start of study intervention\n* Concurrent treatment with nonpermitted drugs\n* Prior participation in a M7824 clinical trial\n* Prior therapy with other immunotherapy or checkpoint inhibitors, such as anti-PD 1, anti PD L1, anti- cytotoxic T-cell lymphocyte-4 (CTLA-4) antibodies.\n* Pregnancy or breast feeding\n* Systemic anticancer treatment after failing 1L platinum-based chemotherapy\n* Other protocol defined exclusion criteria could apply",
        "miscellaneous_criteria": "Inclusion Criteria\n\n* Are participants with histologically or cytologically confirmed locally advanced or metastatic BTC.\n* Availability of tumor (primary or metastatic) archival material or fresh biopsies is mandatory\n* Participants with BTC must have failed or be intolerant to 1L systemic platinum-based chemotherapy administered for locally advanced or metastatic disease. Only one prior treatment line is allowed\n* Disease must be measurable with at least 1 unidimensionally measurable lesion by RECIST 1.1\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 1\n* Life expectancy >= 12 weeks as judged by the Investigator\n* Adequate hematological function defined by white blood cell (WBC) count >= 3 * 10^9/Litre with absolute neutrophil count (ANC) >= 1.5 * 109/Litre, lymphocyte count >= 0.5 * 10^9/Litre, platelet count >=75 * 10^9/Litre, and hemoglobin (Hgb) >= 9 grams/decilitre\n* Adequate hepatic function defined by a total bilirubin level =< 1.5 * upper limit of normal (ULN), an aspartate aminotransferase (AST) level =< 2.5 * ULN, and an alanine aminotransferase (ALT) level =<2.5 * ULN. For participants with liver involvement in their tumor, AST =< 5.0 * ULN and ALT =< 5.0 * ULN is acceptable\n* Adequate coagulation function defined as prothrombin time (PT) or international normalized ratio (INR) =< 1.5 * ULN unless the participant is receiving anticoagulant therapy\n* Albumin >= 3.0 grams/decilitre\n* Hepatitis B virus (HBV) deoxyribonucleic acid (DNA) positive participants must be treated and on a stable dose of antivirals\n* Adequate renal function defined by either creatinine =< 1.5 * ULN or an estimated creatinine clearance (CCr) > 40 milliliter (mL) per minute (min) according to the Cockcroft-Gault formula or by measure of CCr from 24-hour urine collection\n* Other protocol defined inclusion criteria could apply"
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Prior participation in a M7824 clinical trial",
            "criterions": [
                {
                    "exact_snippets": "Prior participation in a M7824 clinical trial",
                    "criterion": "participation in a M7824 clinical trial",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who were not eligible for or have not been treated with 1L systemic chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "not eligible for ... 1L systemic chemotherapy",
                    "criterion": "eligibility for first-line systemic chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "have not been treated with 1L systemic chemotherapy",
                    "criterion": "prior treatment with first-line systemic chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ampullary cancer was excluded",
            "criterions": [
                {
                    "exact_snippets": "Ampullary cancer was excluded",
                    "criterion": "ampullary cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Interstitial lung disease or its history",
            "criterions": [
                {
                    "exact_snippets": "Interstitial lung disease or its history",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "presence or history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concurrent treatment with nonpermitted drugs",
            "criterions": [
                {
                    "exact_snippets": "Concurrent treatment with nonpermitted drugs",
                    "criterion": "concurrent treatment with nonpermitted drugs",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other protocol defined exclusion criteria could apply",
            "criterions": [
                {
                    "exact_snippets": "Other protocol defined exclusion criteria could apply",
                    "criterion": "other protocol defined exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Significant acute or chronic infections",
            "criterions": [
                {
                    "exact_snippets": "Significant acute or chronic infections",
                    "criterion": "infections",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "acute",
                                "chronic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "that might deteriorate when receiving an immunostimulatory agent",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "risk of deterioration with immunostimulatory agent",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Systemic anticancer treatment after failing 1L platinum-based chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "Systemic anticancer treatment after failing 1L platinum-based chemotherapy",
                    "criterion": "systemic anticancer treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": "received after failing 1L platinum-based chemotherapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "failing 1L platinum-based chemotherapy",
                    "criterion": "1L platinum-based chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment outcome",
                            "expected_value": "failed"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Anticancer treatment within 21 days before the start of study intervention",
            "criterions": [
                {
                    "exact_snippets": "Anticancer treatment within 21 days before the start of study intervention",
                    "criterion": "anticancer treatment",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnancy or breast feeding",
            "criterions": [
                {
                    "exact_snippets": "Pregnancy",
                    "criterion": "pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breast feeding",
                    "criterion": "breast feeding",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "currently breastfeeding"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior therapy with other immunotherapy or checkpoint inhibitors, such as anti-PD 1, anti PD L1, anti- cytotoxic T-cell lymphocyte-4 (CTLA-4) antibodies.",
            "criterions": [
                {
                    "exact_snippets": "Prior therapy with other immunotherapy or checkpoint inhibitors, such as anti-PD 1, anti PD L1, anti- cytotoxic T-cell lymphocyte-4 (CTLA-4) antibodies.",
                    "criterion": "prior therapy with immunotherapy or checkpoint inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "history of prior therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy type",
                            "expected_value": [
                                "immunotherapy",
                                "checkpoint inhibitors",
                                "anti-PD 1",
                                "anti PD L1",
                                "anti-CTLA-4 antibodies"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "* Other protocol defined inclusion criteria could apply",
            "criterions": [
                {
                    "exact_snippets": "Other protocol defined inclusion criteria could apply",
                    "criterion": "other protocol defined inclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 1",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Are participants with histologically or cytologically confirmed locally advanced or metastatic BTC.",
            "criterions": [
                {
                    "exact_snippets": "histologically or cytologically confirmed",
                    "criterion": "BTC diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced or metastatic BTC",
                    "criterion": "BTC stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate coagulation function defined as prothrombin time (PT) or international normalized ratio (INR) =< 1.5 * ULN unless the participant is receiving anticoagulant therapy",
            "criterions": [
                {
                    "exact_snippets": "Adequate coagulation function defined as prothrombin time (PT) or international normalized ratio (INR) =< 1.5 * ULN unless the participant is receiving anticoagulant therapy",
                    "criterion": "coagulation function (prothrombin time or international normalized ratio)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy >= 12 weeks as judged by the Investigator",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy >= 12 weeks as judged by the Investigator",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hepatitis B virus (HBV) deoxyribonucleic acid (DNA) positive participants must be treated and on a stable dose of antivirals",
            "criterions": [
                {
                    "exact_snippets": "Hepatitis B virus (HBV) deoxyribonucleic acid (DNA) positive",
                    "criterion": "Hepatitis B virus (HBV) DNA",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must be treated and on a stable dose of antivirals",
                    "criterion": "antiviral treatment for HBV",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose stability",
                            "expected_value": "stable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate renal function defined by either creatinine =< 1.5 * ULN or an estimated creatinine clearance (CCr) > 40 milliliter (mL) per minute (min) according to the Cockcroft-Gault formula or by measure of CCr from 24-hour urine collection",
            "criterions": [
                {
                    "exact_snippets": "creatinine =< 1.5 * ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "estimated creatinine clearance (CCr) > 40 milliliter (mL) per minute (min) according to the Cockcroft-Gault formula",
                    "criterion": "estimated creatinine clearance (CCr) (Cockcroft-Gault)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 40,
                                "unit": "mL/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "measure of CCr from 24-hour urine collection",
                    "criterion": "measured creatinine clearance (CCr) (24-hour urine collection)",
                    "requirements": [
                        {
                            "requirement_type": "measurement",
                            "expected_value": "measured by 24-hour urine collection"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with BTC must have failed or be intolerant to 1L systemic platinum-based chemotherapy administered for locally advanced or metastatic disease. Only one prior treatment line is allowed",
            "criterions": [
                {
                    "exact_snippets": "Participants with BTC",
                    "criterion": "biliary tract cancer (BTC) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have failed or be intolerant to 1L systemic platinum-based chemotherapy administered for locally advanced or metastatic disease",
                    "criterion": "prior 1L systemic platinum-based chemotherapy for locally advanced or metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "treatment failure or intolerance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Only one prior treatment line is allowed",
                    "criterion": "number of prior treatment lines",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Availability of tumor (primary or metastatic) archival material or fresh biopsies is mandatory",
            "criterions": [
                {
                    "exact_snippets": "Availability of tumor (primary or metastatic) archival material or fresh biopsies is mandatory",
                    "criterion": "tumor archival material or fresh biopsies",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Disease must be measurable with at least 1 unidimensionally measurable lesion by RECIST 1.1",
            "criterions": [
                {
                    "exact_snippets": "Disease must be measurable",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 1 unidimensionally measurable lesion",
                    "criterion": "unidimensionally measurable lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "by RECIST 1.1",
                    "criterion": "measurable lesion assessment method",
                    "requirements": [
                        {
                            "requirement_type": "assessment method",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hepatic function defined by a total bilirubin level =< 1.5 * upper limit of normal (ULN), an aspartate aminotransferase (AST) level =< 2.5 * ULN, and an alanine aminotransferase (ALT) level =<2.5 * ULN. For participants with liver involvement in their tumor, AST =< 5.0 * ULN and ALT =< 5.0 * ULN is acceptable",
            "criterions": [
                {
                    "exact_snippets": "total bilirubin level =< 1.5 * upper limit of normal (ULN)",
                    "criterion": "total bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase (AST) level =< 2.5 * ULN",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) level =<2.5 * ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "For participants with liver involvement in their tumor, AST =< 5.0 * ULN",
                    "criterion": "aspartate aminotransferase (AST) level (with liver involvement)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5.0,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "For participants with liver involvement in their tumor, ... ALT =< 5.0 * ULN",
                    "criterion": "alanine aminotransferase (ALT) level (with liver involvement)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5.0,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Albumin >= 3.0 grams/decilitre",
            "criterions": [
                {
                    "exact_snippets": "Albumin >= 3.0 grams/decilitre",
                    "criterion": "albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3.0,
                                "unit": "grams/decilitre"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": [
        {
            "line": "Inclusion Criteria",
            "criterions": []
        },
        {
            "line": "* Adequate hematological function defined by white blood cell (WBC) count >= 3 * 10^9/Litre with absolute neutrophil count (ANC) >= 1.5 * 109/Litre, lymphocyte count >= 0.5 * 10^9/Litre, platelet count >=75 * 10^9/Litre, and hemoglobin (Hgb) >= 9 grams/decilitre",
            "criterions": [
                {
                    "exact_snippets": "white blood cell (WBC) count >= 3 * 10^9/Litre",
                    "criterion": "white blood cell (WBC) count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "10^9/Litre"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "absolute neutrophil count (ANC) >= 1.5 * 10^9/Litre",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "10^9/Litre"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "lymphocyte count >= 0.5 * 10^9/Litre",
                    "criterion": "lymphocyte count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "10^9/Litre"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "platelet count >=75 * 10^9/Litre",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "10^9/Litre"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "hemoglobin (Hgb) >= 9 grams/decilitre",
                    "criterion": "hemoglobin (Hgb)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "grams/decilitre"
                            }
                        }
                    ]
                }
            ]
        }
    ]
}